QUIAPEG PHARMACEUTICALS AB has a total of 42 patent applications. It increased the IP activity by 266.0%. Its first patent ever was published in 2011. It filed its patents most often in United States, Australia and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, biotechnology and foods and drinks are REMEGEN LTD, AMAL THERAPEUTICS SA and VIROMETIX AG.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 11 | |
#2 | Australia | 9 | |
#3 | EPO (European Patent Office) | 6 | |
#4 | Canada | 5 | |
#5 | WIPO (World Intellectual Property Organization) | 3 | |
#6 | Brazil | 2 | |
#7 | China | 2 | |
#8 | Republic of Korea | 2 | |
#9 | Taiwan | 2 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Foods and drinks | |
#4 | Organic fine chemistry | |
#5 | Macromolecular chemistry and polymers |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Peptides | |
#4 | Microorganisms | |
#5 | Enzymes | |
#6 | Special macromolecular compounds | |
#7 | Special acyclic compounds |
# | Name | Total Patents |
---|---|---|
#1 | Kwiatkowski Marek | 40 |
#2 | Sund Christian | 19 |
#3 | Marek Kwiatkowski | 2 |
#4 | Christian Sund | 2 |
Publication | Filing date | Title |
---|---|---|
US2020108124A1 | Releasable glp-1 conjugates | |
CN111629759A | Releasable antibody conjugates | |
EP3592393A1 | Releasable conjugates | |
AU2013276219A1 | Conjugates of biologically active molecules to functionalized polymers |